Back to Search
Start Over
Growth hormone therapy and bone mineral density in Turner syndrome.
- Source :
-
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2004 Oct; Vol. 89 (10), pp. 4886-9. - Publication Year :
- 2004
-
Abstract
- In a previous report, preliminary data showed a significant reduction in cortical bone mineral density (BMD) in women with Turner syndrome that had been treated with GH compared with women with Turner syndrome that had not been treated. To clarify this point, we have investigated the effects of GH treatment at multiple sites in this case-control, cross-sectional study. There were 23 women per group, who were similar in age, height, body mass index, estrogen use, and ethnic makeup. Median age (range) at start and duration of GH treatment was 9 (3-17) and 5 (2-9) yr, respectively. GH-treated women had a slightly greater ( approximately 8%, P = 0.03) width of the radial shaft, but otherwise there were no significant differences between groups in bone dimensions or BMD at the distal radius, lumbar spine, or femoral neck. Furthermore, regression analysis in a linear model including independent variables of age, age at diagnosis, body mass index, presence of spontaneous puberty, and GH use confirmed that GH use did not contribute to variation in BMD.
- Subjects :
- Adolescent
Adult
Bone Diseases etiology
Case-Control Studies
Child
Cross-Sectional Studies
Female
Femur Neck
Growth Disorders etiology
Hip Joint
Humans
Lumbar Vertebrae
Bone Density drug effects
Bone Diseases drug therapy
Growth Disorders drug therapy
Human Growth Hormone therapeutic use
Turner Syndrome complications
Subjects
Details
- Language :
- English
- ISSN :
- 0021-972X
- Volume :
- 89
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- The Journal of clinical endocrinology and metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 15472180
- Full Text :
- https://doi.org/10.1210/jc.2004-0481